Ilary Ruscito

PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?

Maria Luisa Gasparri, Erlisa Bardhi, Ilary Ruscito et al. · Geburtshilfe und Frauenheilkunde · 2017 · 134 citations · Full text

Medicine, Oncology, Pharmacology +17

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)

Ilary Ruscito, Desislava Dimitrova, Inês Vasconcelos et al. · European Journal of Cancer · 2014 · 101 citations

Life Sciences, Genetics, Oncology +17

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway

Ilaria Grazia Zizzari, Chiara Napoletano, Andrea Botticelli et al. · Cancer Immunology Research · 2018 · 62 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets

Chiara Napoletano, Ilary Ruscito, Filippo Bellati et al. · Journal of Clinical Medicine · 2019 · 43 citations · Full text

Medicine, Immunology, Oncology +17

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS) Consortium

Ilary Ruscito, Dan Cacsire Castillo‐Tong, Ignace Vergote et al. · European Journal of Cancer · 2017 · 41 citations · Full text

Medicine, Cancer Biology, Oncology +16